Search company, investor...
Lycera company logo


Founded Year



Loan | Alive

Total Raised


Last Raised

$680K | 3 yrs ago

About Lycera

Lycera is a biopharmaceutical company pioneering approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting pathways to develop new classes of selective, oral immunomodulators for the treatment of patients with diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera's goal is to develop drug candidates with efficacy and safety profiles that change the treatment paradigm for patients with autoimmune diseases. Based on preclinical studies, the company's emerging drug candidates demonstrate improved oral efficacy and/or safety compared to the current standard-of-care antiproliferative and immunosuppressive agents.

Headquarters Location

2800 Plymouth Road NCRC, Building 26

Ann Arbor, Michigan, 48109,

United States


Missing: Lycera's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lycera's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lycera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lycera is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Lycera Patents

Lycera has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Autoimmune diseases
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Designer drugs, Cannabinoids, Ion channels, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Clusters of differentiation, Designer drugs, Cannabinoids, Ion channels, Monoclonal antibodies



Latest Lycera News

Adjunctive Cal/BD foam treatment safe, effective option for difficult-to-treat psoriasis

Mar 21, 2022

Disclosures: Bagel reports financial relationships with AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, CorEvitas LLC, Dermavant Sciences Inc., Dermira/UCB, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Janssen Biotech, Kadmon Corporation, LEO Pharma, Lycera Corp., Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro Pharmaceutical Industries Ltd., Bausch Health Companies and Valeant Pharmaceuticals. Nelson reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Plaque psoriasis patients who had residual plaques following ixekizumab saw success with adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, according to a study. “Pivotal clinical trials have shown ixekizumab to be highly efficacious for the treatment of moderate to severe plaque psoriasis , with nearly 40% of patients showing complete resolution of psoriatic plaques (ie, 100% improvement in the Psoriasis Area and Severity Index) after 12 weeks of treatment. However, a considerable proportion of patients (60%-65%) continue to have residual plaques after 12 weeks of treatment,” Jerry Bagel, MD, MS, and Elise Nelson, LPN, CCRC, of the Psoriasis Treatment Center of New Jersey, wrote. This prospective, open-label, single-arm study evaluated patients at a single center who had 3% to 8% residual body surface area (BSA) involvement following ixekizumab treatment for 24 weeks or longer. The 25 enrolled patients remained on ixekizumab but were also instructed to apply a foam formulation of calcipotriene 0.005% and betamethasone dipropionate 0.064% (Cal/BD) daily for 4 weeks. Following this initial phase, patients were instructed to use the Cal/BD foam every other day through week 12. After the 4-week initial treatment phase, 56% of patients achieved the treatment goal of 1% BSA or less and 56% achieved Physician Global Assessment (PGA) scores of 1 or less. The mean BSA decreased by 55%, while the mean PGA score decreased by 49%. After 12 weeks, 64% achieved the treat-to-target goal. In addition, Dermatology Life Quality Index scores decreased by 2.3 points. “In this observational, real-world study of patients with moderate to severe plaque psoriasis, the addition of Cal/BD foam was associated with notable improvements in disease outcomes in patients who had suboptimal response after treatment with ixekizumab for [at least] 24 weeks,” the authors wrote. “Among patients with a suboptimal response to biologic therapy, adjunctive treatment with Cal/BD foam offers patients with difficult to treat psoriasis a safe and versatile treatment option, which may improve disease control and long-term management of psoriasis.” Read more about

Lycera Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lycera Rank

Lycera Frequently Asked Questions (FAQ)

  • When was Lycera founded?

    Lycera was founded in 2006.

  • Where is Lycera's headquarters?

    Lycera's headquarters is located at 2800 Plymouth Road, Ann Arbor.

  • What is Lycera's latest funding round?

    Lycera's latest funding round is Loan.

  • How much did Lycera raise?

    Lycera raised a total of $87.57M.

  • Who are the investors of Lycera?

    Investors of Lycera include Paycheck Protection Program, InterWest Partners, ARCH Venture Partners, Clarus, Third Rock Ventures and 3 more.

  • Who are Lycera's competitors?

    Competitors of Lycera include Gentronix Limited, Echelon Biosciences, Promentis Pharmaceuticals, Creabilis Therapeutics, KineMed and 13 more.

Compare Lycera to Competitors

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.


Alzheimer's Disease is a modern curse that negates the many benefits from modern medicine and improved standards of hygiene and living. As the human population life-span is increased, a larger percentage of people will succumb to debilitating and distressing memory loss. Alzeim is dedicated to making available a natural plant alkaloid " Galanthamine (also widely called Galantamine) - that is proven to be a drug in the alleviation of memory-loss symptoms.nIt has few adverse side-effects and is currently extremely expensive to produce either from wild plants or by synthesis. By the application of research adding to its existing framework of knowledge, the company is establishing a new agri-industry in an upland region of Wales. Once production is adequate, it will make Galanthamine more widely available and affordable. Daffodils grown in the Black Mountains - helping Alzheimer's patientsnnGalanthamine has been known for some time as one of the few effective treatments for patients at certain stages of Alzheimer's Disease, having been produced in its natural form from plants found in the wild " principally in the Balkan region. This natural alkaloid is currently in short supply and because of the large number of potential patients (c. 700,000 currently in UK) is a very expensive treatment in total for a health provider to assume. In Scotland all patients who can benefit from it, and from related drugs, have access on prescription, but in England and Wales, the National Institute for Clinical Excellence (NICE) has decided to withdraw all anti-cholinesterase treatments from the National Health Service as regards new patients, because of the high total cost of branded medicines still subject to restrictive product licence. That decision has caused an outcry from sufferers and their families, and is being disputed in the High Court. It may not be resolved until after the drugs are able to be produced and sold in generic form. Nevertheless, global demand for Galanthamine is expanding rapidly. Alzeim expects to be able to provide much-needed extra quantities of the drug at lower prices thereby enabling many more patients to benefit from this treatment. Field trials, plant species and variety screening and laboratory extraction, purification and analysis work undertaken initially in co-operation with the IGER institute of University of Wales, Aberystwyth, indicated that a feasible route existed to produce Galanthamine economically in special regimes in parts of Mid-Wales. Since then, using mechanization under agronomic conditions, Alzeim has developed new production regimes with its own cultivars.nAmong other academic collaborations Alzeim is working on aspects of Galanthamine extraction and purification with the University of Manchester.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.

Nanion Technologies GmbH

Nanion Technologies is a spin-off company from the Center of Nanoscience (CeNS) of the University of Munich (LMU). anion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. anion bases its business on a chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for medicines aimed at many important diseases.

Melior Discovery

Melior Discovery has develops an optimized, high throughput pharmacology platform that is able to systematically identify indications for pre-clinical and development stage drug candidates. Melior also applies this expertise to the provision of a range of essential pre-clinical and discovery services for clients in the pharmaceutical and biopharmaceutical industries, including pharmacokinetic evaluations, efficacy models and bioanalytical testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.